Detailed genomic profiling across the spectrum of CHD

CardioRegen genomic studies are fully integrated with the gene discovery pipeline established by the Australian Genomic Health Alliance Cardiovascular Flagship.

The four priority areas are:

1. Genomic profiling of patients with cardiomyopathies,
2. Whole genome sequencing of patients across the spectrum of aortic arch obstructions,
3. Identification of genetic variants in chemotherapy-induced cardiomyopathy,
4. Genomic and transcriptomic analysis of patients with dilated cardiomyopathy.